Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jürgen Alt"'
Autor:
Sofia Hornetz, Daniel C. Christoph, Helge Bischoff, Sebastian Michels, M Kimmich, Jürgen Alt, Monica Schäfer, Werner Spengler, Frank Griesinger, Martin Sebastian, Annette Müller, Jan Stratmann, Eckart Laack, S. Sackmann
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 144:2457-2463
Osimertinib, a third-generation irreversible mutant-selective inhibitor of EGFR kinase activity was clinically evaluated in the AURA trials, where it showed high clinical efficacy and a favorable toxicity profile in patients with acquired exon 20-EGF
Autor:
Stephanie Dille, A. Fleitz, Jacqueline Rauh, Lukas C. Heukamp, Marlen Sandberg, Tobias Dechow, Albrecht Stenzinger, Frank Griesinger, Mike Thomas, Konrad Kokowski, Matthias Groschek, Wilko Weichert, Wolfgang Schütte, Wilfried Eberhardt, Jürgen Alt, Reinhard Büttner, Stefan Zacharias, Martin Sebastian, Martina Jänicke, Eyck von der Heyde, Thomas Wehler, A. Hipper, Petra Hoffknecht, Martin Metzenmacher
Objectives: After decades of unsuccessful efforts in inhibiting KRAS, promising clinical data targeting the mutation subtype G12C emerge. Since little is known about outcome with standard treatment of patients with G12C mutated non-small cell lung ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99033094ddf7a1abf8a1507bdf20369e
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85100908806
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85100908806
Autor:
Ralf Marienfeld, Martin Wermke, Alexander Desuki, Marcel Wiesweg, Daniela Aust, Maria Joosten, Gerlinde Schmidtke-Schrezenmeier, Carina Wenzel, Jan Stratmann, Johannes Berger, Felix C. Saalfeld, Sebastian Thiel, Sonja Loges, Thomas Herold, Michael Thomas, Jürgen Alt, Michael Kramer, Silke Laßmann, Martin Sebastian, Susann Stephan-Falkenau, Timm M. Reissig, Albrecht Stenzinger, Jürgen Wolf, Cornelius F. Waller, Petros Christopoulos, Janna-Lisa Velthaus, Sylvia Herold, Amanda Tufman, Sabine Merkelbach-Bruse, Sebastian Michels, Diego Kauffmann-Guerrero
Introduction In contrast to other driver mutations, no targeted therapies have yet been approved in ERBB2-mutated NSCLC (HER2mu NSCLC). Nevertheless, several compounds have revealed promising early efficacy data, which need to be evaluated in the con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da498ab56de3a9cf9f9ed770a2f41b31
https://www.ncbi.nlm.nih.gov/pubmed/34245914
https://www.ncbi.nlm.nih.gov/pubmed/34245914
Autor:
Wolfgang M. Brückl, Felix Steger, Jürgen Alt, M. Faehling, Philipp Schütt, Petra Hoffknecht, Anke Schlenska-Lange, Marlitt Horn, Daniel C. Christoph, Christian Schumann, Petros Christopoulos, Stephan Eisenmann
Publikováno v:
Data in Brief
Data in Brief, Vol 34, Iss, Pp 106556-(2021)
Data in Brief, Vol 34, Iss, Pp 106556-(2021)
Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.201
Autor:
Geothy Chakupurakal, Jan Stratmann, Irene Krämer, Marius Fried, Jelena Rosentreter, Jürgen Alt
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(5)
Introduction Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suff
Autor:
Ernst Späth-Schwalbe, Sebastian Thiel, Jürgen Fischer, Jürgen Alt, Daniel C. Christoph, Frank Griesinger, Sylke Kurz, W. Schütte, Frederik Krefting, Nadezda Basara, M Kimmich
Publikováno v:
Oncology research and treatment. 42(5)
Background: Anti-PD1 monoclonal antibody nivolumab is an approved therapy option for the treatment of advanced squamous cell non-small cell lung cancer (SQ-NSCLC) patients. Data outside clinical trials about therapy efficacy and safety in later thera